Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · May 20, 2026, 6:08 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Reticular Interpretable AI for drug discovery.
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2024). Investors: Y Combinator. (High).
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2024). Investors: Y Combinator. (High).
Product / news
2 product/news‑styled row(s); headline risk without filings (High).
Verified facts
Interpretable AI for drug discovery—steerable protein models for pharma R&D.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
Pricing · Thu, Jul 2, 03:40 PM · confidence 90%high quality
Wed, May 20, 06:08 PM · confidence 88%high quality
Wed, May 20, 06:08 PM · confidence 85%high quality
Newest first · 8 event(s)
Source: Pricing
Answer a few questions and compare Reticular reproductive genetics and embryo analysis plans.
Source: Blog
Explore the science behind reproductive genetics, how Reticular reads embryo data, and the latest research from our team.
Interpretable AI for drug discovery—steerable protein models for pharma R&D.
Company YC launch announcement.
Source: npm_registry
CLI tool for analyzing HTML accessibility announcements
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
Science that empowers the decision of a lifetime.
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗4 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
Answer a few questions and compare Reticular reproductive genetics and embryo analysis plans.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Company YC launch announcement.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Interpretable AI for drug discovery—steerable protein models for pharma R&D.
Why it matters: Funding signal — Pre-Seed per this source; verify against the linked original before relying on it.
Open source ↗1 row(s)
Public engineering activity. Sustained commits, releases, and stars indicate real product development and, for dev tools, developer adoption.
CLI tool for analyzing HTML accessibility announcements
Why it matters: Engineering signal — public repo activity evidences active development and possible developer adoption.
Open source ↗1 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
Explore the science behind reproductive genetics, how Reticular reads embryo data, and the latest research from our team.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.